Traders should monitor upcoming data readouts from the TILS-025 trial, especially TSPO PET imaging results, which could serve as a key efficacy signal. Positive data may catalyze significant re-rating given the absence of disease-modifying therapies for MSA.
Price Chart
Executive Summary
Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a trial of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress in May 2026. This marks a clinical milestone for a therapy targeting neuroinflammation in a disease with no approved disease-modifying treatments.
Key Facts
- Phase 2a trial of intranasal foralumab in MSA accepted for late-breaking poster presentation at the 7th World Parkinson Congress (May 24-27, 2026).
- TILS-025 trial is an open-label study enrolling up to 10 patients with MSA, evaluating intranasal foralumab's effect on microglial activation via TSPO PET imaging and clinical outcomes.
- Primary endpoints include changes in microglial activation (via [F-18]PBR06 TSPO PET) and MDS-UMSARS scores; secondary endpoints include brain atrophy on MRI, autonomic function, quality of life, and immune biomarkers.
- Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, delivered intranasally to modulate neuroinflammation.
Financial Impact
Non-material to current financials but potentially transformative to valuation if trial data shows efficacy, given MSA's high unmet need and lack of approved therapies.
Risk Factors
- Early-stage trial (Phase 2a) with small sample size (up to 10 patients), limiting statistical power.
- Forward-looking statements dominate; no interim or final efficacy data disclosed in this release.
- High development risk typical of neurodegenerative disease trials, where clinical endpoints are difficult to achieve.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273191 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8700 (−13.86%) |
Oct 16, 2026 11d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8700 (+13.86%) |
Oct 16, 2026 11d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8700 (−17.14%) |
Sep 30, 2026 27d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8700 (−21.62%) |
Sep 28, 2026 29d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8700 (−11.22%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8700 (−3.82%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8700 (−10.31%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8700 (−10.31%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8700 (−24.35%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8700 (−10.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers